Roka Bioscience is led by a team of managers experienced in both the science and business of biological testing.
Paul G. Thomas
Founder / Chief Executive Officer
Mr. Thomas joined Roka Bioscience, a company focused on the development and commercialization of rapid, accurate and cost-effective molecular assays for biopharmaceutical processing, food safety and other industrial testing applications, as CEO and Founder in September 2009. Mr. Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation, a publicly traded regenerative medicine company, from 1998 until it was acquired by KCI in 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions during his tenure of 15 years with Ohmeda, a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business and completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his B.S. degree in Chemistry from St. Michael’s College in Vermont. Mr. Thomas serves as a Director of AbioMed, Inc. (NASDAQ: ABMD) a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Mr. Thomas also serves as a Director of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) focused on the commercialization of a life-altering therapy for debilitating and fatal orphan diseases.
Steven T. Sobieski
Senior Vice President / Chief Financial Officer
Mr. Sobieski joined Roka Bioscience in September 2009. He brings to Roka 20 years of financial management experience in a variety of roles in biotechnology and public accounting. Prior to joining Roka, Mr. Sobieski served from 2000 to 2009 as senior vice president and chief financial officer at LifeCell Corporation, a public company focused on developing and marketing reconstructive surgical products. Mr. Sobieski was vice president of finance at Osteotech, Inc., a public company focused on orthopedic products, where he also served in other positions, from 1991 to 2000. From 1981 through 1991, Mr. Sobieski was with Coopers & Lybrand, a public accounting firm. Mr. Sobieski received his BS in business administration from Monmouth University, his MBA degree with a concentration in accounting from Rutgers University, and he is a CPA. Mr. Sobieski serves as a director and chairman of the audit committee of Insulet Corporation, a public medical device company specializing in insulin infusion systems.
Senior Vice President / General Manager
Mr. Narajowski joined Roka Bioscience as SVP and General Manager of the San Diego operation. He comes to Roka with over 25 years of experience in the business of life science. In the industry he is well known for his ability to take new technological concepts and turn them into successful businesses or major product lines. Before joining Roka, Mr. Narajowski served from 2005 to 2008 as president, chief executive officer of Pathway Diagnostics, a biomarker development and testing company, which was sold to Quest Diagnostics. Prior to Pathway, Mr. Narajowski served as vice president, general manager of Focus Diagnostics, an infectious disease reference laboratory and diagnostic product business. The majority of Mr. Narajowski’s career was with Abbott Laboratories where he served as vice president, general manager of critical care products, vice president, general manager of the infusion pump business, general manager of physician office diagnostics, and a director of research and development. Mr. Narajowski received his MS in bioengineering from the University of Utah, and his BS in electrical engineering from the Illinois Institute of Technology.
Senior Vice President, Chief Commercial Officer
Mary Duseau joined Roka Bioscience in February 2015 as Senior Vice President & Chief Commercial Officer. Ms. Duseau has 28 years of commercial experience in the Scientific Research Market where she has held numerous sales and business management positions at Andor, PerkinElmer, Bio-Rad and Stratagene. Prior to joining Roka, Ms. Duseau served as Director of Global Sales and Board member during her two year tenure at Andor Technologies. Andor specializes in scientific imaging, spectroscopy solutions and microscopy systems. At PerkinElmer, Ms. Duseau served 13 years in various business and sales leadership roles. Prior to her departure, she was the Global Vice President of Sales & Marketing. This position was responsible for a team of 350 direct, inside sales and distributor networks along with Marketing and the Product Support Organization to drive more than $350M of annual revenue. Ms. Duseau graduated from the University of Massachusetts at Amherst, with a BS in Biochemistry.
Vice President of Research and Development
Dr. Becker joined Roka Bioscience as Vice President of Assay Research and Development in September 2009. Before joining Roka, Mick worked 16 years at Gen-Probe, Inc. (now Hologic) in the Research Department where he invented a number of key core technologies including 2’methoxy modified primers and probes, specific target capture, nonspecific wobble target capture, smart capture probes and primers, molecular torches, real-time TMA, background reduction technology, and universal alkaline lysis. Mick has published over 100 papers and patents including over 40 issued US patents. Before joining Gen-Probe Mick was an Associate Professor in the Institute of Biosciences and Technology at Texas A&M University, an Assistant Professor in the Department of Biological Sciences at the University of Pittsburgh and an Anna Fuller Postdoctoral Fellow at Harvard with James C. Wang. Mick received his Ph.D. in Chemistry from Caltech in 1981 under Peter B. Dervan.
David R. Patterson
Vice President of Manufacturing Operations
Mr. Patterson joined Roka Bioscience as Vice President of Operations in September 2009. He has 18 years of experience in a variety of roles in the biotechnology field. Prior to joining Roka Bioscience, Mr. Patterson served as the Associate Director of Process Transfer at Gen-Probe, Inc. (now Hologic) responsible for scaling up, transferring, and launching assays, most notably the Procleix West Nile Virus and Ultrio (HIV-1/HCV/HBV) assays marketed by Novartis. Mr. Patterson’s 10 year tenure at Gen-Probe also included the following positions: Scientist on the HIV-1/HCV assay development team, Manager of the Process Support group, and Manager of Process Transfer. In addition, Mr. Patterson held various roles over 8 years at Ortho-Clinical Diagnostics, a subsidiary of Johnson & Johnson. He began as a research scientist where he earned patents in real-time PCR, carryover prevention methodology, and detection of HIV-1/HCV. He completed his career at Ortho-Clinical as the Operation’s Supervisor of the FDA (CBER) approved manufacturing facility for blood screening tests. Mr. Patterson received his B.S. degree in Biochemistry from the University of California at Riverside.
Vice President of Finance
Mr. Boesgaard joined Roka Bioscience in October 2009. Lars has more than 16 years’ experience in financial management, obtained primarily in the life sciences industries. Before joining Roka, Mr. Boesgaard was Vice President of Finance at Insulet Corporation from 2007 to 2009. From 2004 to 2007, Mr. Boesgaard served as Sr. Director of Financial Services for Alexion Pharmaceuticals, Inc. Mr. Boesgaard began his career holding various finance positions at Novo Nordisk A/S in Denmark and Japan. Mr. Boesgaard earned a BS in business administration from Copenhagen Business School and an MBA from the Richard Ivey School of Business at Western University in Ontario, Canada.